Although TNFR2 cannot regulate the expression of Fas in pancreatic cancer cells, an anti-FasL antibody could partially reverse the effect of the tumor cells’ decreased resistance to lymphocytes under Tnfr2 KD or when treated with anti-TNFR2 antibody (online supplemental figure 6I-K). Here, FASLG is linked to familial pancreatic carcinoma.